World OTC Pharmaceutical Market 2013-2023

NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World OTC Pharmaceutical Market 2013-2023

http://www.reportlinker.com/p0943305/World-OTC-Pharmaceutical-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug

Report Details
Discover the highest potential revenues in over-the-counter medicine

What does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and prospects there.

Our study lets you assess OTC (over-the-counter) pharmaceuticals: medicines sold without prescriptions. It lets you assess projected sales at world market, therapeutic submarket, product and national level to 2023. There you see financial results, interviews, trends, opportunities, and revenue predictions.

Forecasts and other data to help you stay ahead

You see forecasting of six world-level submarkets to 2023, finding potential revenues:
• Cough, Cold and Allergy
• Analgesics/pain relievers
• Gastrointestinals
• Dermatological treatments
• Smoking cessation products
• Other relevant sales in consumer healthcare.

The analyses exclude vitamins, minerals and other nutritional products.

Also, how will leading products - including Tylenol, Nicorette, Panadol and Advil - perform from 2013 to 2023? Discover qualitative analyses too. You also gain 63 figures, 97 tables and four interviews with authorities in the industry.

Prospects for leading countries shown to 2023

Developments worldwide will influence the market, especially fast-rising demand in emerging markets.

You discover revenue forecasts to 2023 for eleven national markets:
• US
Japan
Germany, France, UK, Italy, and Spain (EU5 nations)
India
China
Brazil
Russia.

This decade, revenues from India and China will be among the fastest growing worldwide.

Discussions of leading companies and prospects for market growth

Our work shows you what products and organisations hold greatest potential. See profiles of 12 leading companies, including these:

• Bayer
• GSK
• Johnson and Johnson
• Novartis
• Reckitt Benckiser
• Perrigo
• Pfizer.

In general, a company profile gives you the following information
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations.
• OTC sales forecast to 2023

Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will competition have? Brand extensions and OTC switching will change the industry.

Ways World OTC Pharmaceutical Market 2013-2023 helps you

In summary, then, our research and analysis give you the following knowledge:
• Revenues to 2023 for the overall world market and submarkets- discover that industry's prospects, finding promising places for investments and revenues
• Potential revenues of leading OTC products and portfolios to 2023
• Assess 12 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia
• Review prospects for Rx-to-OTC switching by therapeutic area
• View opinions from our survey, seeing interviews with authorities.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

1. Executive Summary

1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods

2. Introduction to OTC Pharmaceuticals

2.1 What are OTC Pharmaceuticals?
2.2 Classification of OTC Pharmaceuticals
2.3 The Main Features of OTC Pharmaceuticals
2.4 OTC Switching
2.4.1 How is a Drug Switched from Prescription to OTC?
2.5 Manufacturing and Distribution of OTC Pharmaceuticals
2.6 Regulation of OTC Pharmaceuticals
2.6.1 Regulation of OTC Pharmaceuticals in the US
2.6.2 Regulation of OTC Pharmaceuticals in Japan
2.6.3 Regulation of OTC Pharmaceuticals in Europe
2.6.4 Regulation of OTC Pharmaceuticals in Other Countries
2.7 OTC Pharmaceuticals: Market Segmentation
2.7.1 Analgesics
2.7.1.1 Internal Analgesics
2.7.1.2 External Analgesics
2.7.2 Cough, Cold and Allergy Products
2.7.2.1 Cough and Cold Remedies
2.7.2.2 Anti-Allergy Products
2.7.3 Dermatological Products
2.7.3.1 Minor Cuts and Wounds
2.7.3.2 Acne
2.7.3.3 Rashes, Itchy Skin, and Dermatitis/Eczema
2.7.3.4 Cold Sores
2.7.3.5 Warts
2.7.3.6 Fungal Skin Infections
2.7.3.7 Haemorrhoids
2.7.3.8 Other Dermatological Products
2.7.4 Gastrointestinal Products
2.7.4.1 Indigestion and Heartburn
2.7.4.2 Anti-Diarrhoea OTC Pharmaceuticals
2.7.4.3 Laxatives
2.7.4.4 Anti-Emetic OTC Pharmaceuticals
2.7.4.5 Anti-Obesity OTC Pharmaceuticals
2.7.5 Smoking Cessation Aids
2.7.6 Other OTC Pharmaceuticals
2.7.7 Vitamins, Minerals and Supplements

3. The World OTC Pharma Market 2013-2023

3.1 The World OTC Pharma Market in 2012
3.1.1 OTC Pharma Market Segmentation, 2012
3.1.2 Leading OTC Pharma Brands, 2012
3.1.3 Leading Companies in the OTC Market, 2012
3.2 The World OTC Pharma Market: Sales Forecast, 2013-2023
3.3 OTC Pharma Market Segments: Sales Forecasts, 2013-2023
3.3.1 CAGRs by OTC Segment, 2013-2023
3.3.2 Changing Market Shares by OTC Segment, 2013-2023
3.3.3 Cough, Cold and Allergy Drugs Lead the OTC Market
3.3.4 Analgesic OTC Drugs: Moderate Growth
3.3.5 Gastrointestinal OTC Drugs: Steady Growth
3.3.6 Dermatological OTC Drugs: Strong Growth
3.3.7 Smoking Cessation Aids Will Grow in Emerging Markets
3.3.8 OTC Switching Will Create New OTC Markets

4. The Leading National Markets 2013-2023

4.1 Regional Breakdown of the World OTC Pharma Market, 2012
4.2 The World OTC Pharmaceutical Market: Regional Forecast, 2013-2023
4.3 Changing Market Shares of Leading National Markets, 2013-2023
4.4 The OTC Pharmaceutical Market in the US, 2013-2023
4.4.1 The US OTC Pharma Market: Leading Companies
4.5 The OTC Pharmaceutical Market in Japan to 2023
4.5.1 The Japanese OTC Pharma Market: Leading Companies
4.6 The OTC Pharmaceutical Market in China to 2023
4.6.1 The Chinese OTC Pharma Market: Leading Companies
4.6.2 The Chinese OTC Pharma Market: An Overview
4.6.3 The Chinese OTC Pharma Market: Regulation and Reimbursement
4.7 The OTC Pharmaceutical Market in the Five Leading European National Markets to 2023
4.7.1 The EU5 OTC Pharma Market: Leading Companies
4.7.2 The OTC Pharmaceutical Market in Germany to 2023
4.7.3 The OTC Pharmaceutical Market in the UK to 2023
4.7.4 The OTC Pharmaceutical Market in France to 2023
4.7.5 The OTC Pharmaceutical Market in Italy to 2023
4.7.6 The OTC Pharmaceutical Market in Spain to 2023
4.8 The OTC Pharmaceutical Market in Russia to 2023
4.8.1 The Russian OTC Pharma Market: Leading Companies
4.8.2 The Russian OTC Pharma Market: Overview
4.9 The OTC Pharmaceutical Market in India to 2023
4.9.1 The Indian OTC Pharma Market: Leading Companies
4.9.2 The Indian OTC Pharma Market: An Overview
4.10 The OTC Pharmaceutical Market in Brazil to 2023
4.10.1 The Brazilian OTC Pharma Market: Leading Companies
4.10.2 The Brazilian OTC Pharma Market: An Overview

5. Leading Companies in the OTC Pharma Market 2013-2023

5.1 Leading OTC Pharmaceutical Manufacturers, 2012
5.2 Leading OTC Pharma Companies: Sales Forecasts, 2013-2023
5.3 Bayer
5.3.1 Bayer: OTC Sales Forecast, 2013-2023
5.3.2 Bayer Aspirin
5.3.2.1 Bayer Aspirin: Sales Forecast, 2013-2023
5.4 Boehringer Ingelheim
5.4.1 Boehringer Ingelheim: OTC Sales Forecast, 2013-2023
5.4.2 The Dulcolax Franchise
5.4.3 Mucosolvan/Lasolvan and Other OTC Products
5.5 GSK
5.5.1 GSK: OTC Sales Forecast, 2013-2023
5.5.2 Panadol
5.5.2.1 Panadol: Sales Forecast, 2013-2023
5.5.3 Alli
5.5.4 GSK Smoking Cessation Products
5.6 Johnson & Johnson
5.6.1 FDA Governance of McNeil Manufacturing Activity
5.6.2 Expansion in Developing Markets through Acquisitions
5.6.3 Johnson & Johnson: OTC Sales Forecast, 2013-2023
5.6.4 Tylenol
5.6.4.1 Tylenol: Sales Forecast, 2013-2023
5.6.5 Nicorette
5.7 Merck
5.7.1 Merck: OTC Sales Forecast, 2013-2023
5.7.2 Merck Withdraws from Joint Venture with Johnson & Johnson
5.7.3 FDA Approval of First-in-Class Switch: Oxytrol for Women
5.7.4 Claritin OTC (loratadine)
5.7.4.1 Claritin OTC: Sales Forecast, 2013-2023
5.8 Novartis
5.8.1 Novartis: OTC Sales Forecast, 2013-2023
5.8.2 Resolving Manufacturing Problems at Lincoln, Nebraska
5.9 Perrigo
5.9.1 Perrigo: OTC Sales Forecast, 2013-2023
5.9.2 Perrigo is Focused on Organic and Inorganic Growth
5.9.3 Perrigo's Product Launches in FY 2013
5.9.4 Perrigo Benefits from Challenges Faced in the Industry
5.10 Pfizer
5.10.1 Pfizer: OTC Sales Forecast, 2013-2023
5.10.2 Pfizer Acquires Rights to AstraZeneca's OTC Nexium
5.10.3 Pfizer Continues to Expand via Consumer Health Acquisitions
5.10.4 Advil
5.10.4.1 Advil: Sales Forecast, 2013-2023
5.11 Procter & Gamble
5.11.1 PGT Healthcare - Procter & Gamble's Joint Venture with Teva
5.11.2 Prilosec OTC
5.12 Reckitt Benckiser
5.12.1 Reckitt Benckiser: OTC Sales Forecast, 2013-2023
5.12.2 Purchase of Paras Pharmaceuticals and Expansion into Developing Markets
5.13 Sanofi
5.13.1 Sanofi: OTC Sales Forecast, 2013-2023
5.13.2 Sanofi: Consumer Health Acquisitions
5.14 Taisho Pharmaceutical

6. OTC Switching and Prospects for Future OTC Drugs

6.1 OTC Switching: An Overview
6.1.1 What is OTC Switching?
6.1.2 Which Products Will Switch?
6.1.3 How Does OTC Switching Occur?
6.1.4 How Does OTC Switching Affect The OTC Pharma Market?
6.1.5 Opposition to OTC Switching
6.2 Recent OTC Switching Activity
6.2.1 A Decline in OTC Switching?
6.2.2 The FDA NSURE Paradigm May Increase OTC Switch Rates
6.3 Prospects for OTC Switching, 2013-2023
6.4 Cough, Cold and Allergy: OTC Switches
6.4.1 First-Generation Antihistamines
6.4.2 Allegra (fexofenadine)
6.4.3 Clarinex (desloratadine)
6.4.4 Flixotide/Flonase (fluticasone)
6.4.5 Nasacort (triamcinolone)
6.5 Analgesics: OTC Switches
6.5.1 Triptans
6.5.2 NSAIDs for Arthritis
6.5.3 Other Analgesics
6.6 Gastrointestinals: OTC Switches
6.6.1 H2-Receptor Blockers
6.6.2 Proton pump inhibitors (PPIs)
6.6.2.1 Omeprazole
6.6.2.2 Lansoprazole
6.6.2.3 Pantoprazole
6.6.2.4 Esomeprazole
6.6.2.5 Rabeprazole
6.6.3 Anti-obesity drugs
6.7 Dermatologicals: OTC Switches
6.7.1 Antivirals for Oral Herpes Simplex
6.8 Anticholinergics for Incontinence: OTC Switches
6.9 Oral Contraceptives: OTC Switches
6.10 Cholesterol-Lowering Drugs: OTC Switches
6.10.1 Lipitor (atorvastatin)
6.10.2 Zocor Heart Pro (simvastatin) in the UK
6.10.3 Prospects for OTC Statins in the US
6.10.4 Worldwide Prospects for OTC Statins
6.11 Other Potential OTC Switch Categories
6.11.1 Erectile Dysfunction: Viagra (sildenafil)
6.11.2 Insomnia: Silenor (doxepin)
6.11.3 High blood pressure: thiazide diuretics

7. Qualitative Analysis of the OTC Pharma Market, 2013

7.1 SWOT Analysis of the OTC Pharmaceutical Market
7.2 Strengths
7.2.1 Many Pharma Companies Have a Strong Potential OTC Portfolio
7.2.2 Regulators Are Encouraging OTC Approvals
7.2.3 Effective Distribution Networks Due to Expansion of Retail Pharmacy and Alternative Distributors
7.2.4 Cultural Changes Will Support Self-Medication With OTC Medicines
7.3 Weaknesses
7.3.1 Pharma Companies Remain Focused on Prescription Drugs
7.3.2 Manufacturing Problems Affect Sales of Some OTC Products
7.3.3 OTC Products are Vulnerable to Price Controls
7.4 Opportunities
7.4.1 Demographic and Economic Changes Will Create Growth Opportunities
7.4.2 OTC Switching Will Create New Markets and Expand Existing Markets
7.4.3 Strong Growth in Emerging Markets
7.4.4 New Healthcare Technologies May Enable OTC Approvals
7.4.5 Opportunities in Social Media and Online Marketing
7.5 Threats
7.5.1 Competition From Private-Label Brands Will Reduce Profits
7.5.2 Regulatory Concerns May Lead to Withdrawal of Products
7.5.3 Resistance to OTC Switching From Some Groups
7.6 Porter's Five Forces Analysis of the OTC Pharmaceutical Market
7.7 Rivalry Among Competitors [High]
7.8 Threat of New Entrants [Medium]
7.9 Power of Suppliers [Low]
7.10 Power of Buyers [Medium]
7.11 Threat of Substitutes [High]

8. Research Interviews

8.1 Interview with Mr David Spangler, Senior Vice President, US Consumer Health Products Association, Washington DC, USA
8.1.1 A Decline In OTC Switches?
8.1.2 How will NSURE affect the OTC pharma market?
8.1.3 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
8.1.4 Is OTC Big Pharma's New Business Model?
8.1.5 Future OTC Switches
8.1.6 How Will US Healthcare Reform Affect the OTC Pharma Market?
8.1.7 New Distribution Channels
8.1.8 Development of the OTC Sector
8.2 Interview with Professor Joshua P. Cohen, PhD, Tufts Center for the Study of Drug Development, Boston, Massachusetts, USA
8.2.1 How will NSURE affect the OTC pharma market?
8.2.2 Will Statins Switch to OTC in the US?
8.2.3 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
8.2.4 Is OTC Big Pharma's New Business Model?
8.2.5 Future OTC Switches
8.2.6 How Will US Healthcare Reform Affect the OTC Pharma Market?
8.2.7 New Distribution Channels
8.3 Interview with Professor Daniel Hussar, Remington Professor of Pharmacy, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA
8.3.1 How will NSURE affect the OTC pharma market?
8.3.2 A Decline In OTC Switches?
8.3.3 Prospects for a Behind-the-Counter Class of OTC Drugs in the US
8.3.4 How Will US Healthcare Reform Affect the OTC Pharma Market?
8.3.5 Is OTC Big Pharma's New Business Model?
8.3.6 Future OTC Switches
8.3.7 New Distribution Channels
8.3.8 Development of the OTC Sector
8.4 Interview with Lisa Kubaska, Spokesperson, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA
8.4.1 What is the Purpose of NSURE?
8.4.2 Impact of NSURE on the OTC Pharmaceutical Market
8.4.3 Prospects for a Behind-the-Counter Class of OTC Drugs in the US

9. Conclusions

9.1 The World OTC Pharma Market in 2012
9.1.1 Leading OTC Product Categories
9.1.2 Leading OTC Pharma Brands, 2012
9.1.3 Leading OTC Pharmaceutical Manufacturers
9.1.4 Leading National Markets
9.1.5 OTC Market Growth
9.1.6 OTC Switching
9.1.7 Emerging OTC Markets
9.2 The Future of the OTC Pharma Market?

List of Tables

Table 2.1 OTC Internal Analgesic Active Ingredients, 2013
Table 2.2 OTC External Analgesic Active Ingredients, 2013
Table 2.3 OTC Cough, Cold and Allergy Active Ingredients, 2013
Table 2.4 OTC Antifungal Active Ingredients, 2013
Table 2.5 OTC Indigestion and Heartburn Active Ingredients, 2013
Table 2.6 OTC Anti-Diarrhoea Active Ingredients, 2013
Table 2.7 OTC Laxative Active Ingredients, 2013
Table 2.8 OTC Smoking Cessation Aid Active Ingredients, 2013
Table 3.1 The World OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by Product Category, 2012
Table 3.2 Top 10 OTC Pharmaceutical Products: Revenues ($m), 2012
Table 3.3 Top 10 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2012
Table 3.4 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.5 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Product Category, 2012-2023
Table 3.6 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2012-2017, 2017-2023 and 2012-2023
Table 3.7 Market Shares (%) of the OTC Pharmaceutical Market, By Category, 2012, 2017 and 2023
Table 3.8 The Cough, Cold and Allergy OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.9 The Analgesics OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.10 The Gastrointestinals OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.11 The Dermatologicals OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.12 The Smoking Cessation Aids OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 3.13 The Other Products OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.1 The World OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by Region, 2012
Table 4.2 The World OTC Pharmaceutical Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Region, 2012-2017
Table 4.3 The World OTC Pharmaceutical Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Region, 2017-2023
Table 4.4 Regional OTC Pharmaceutical Market Forecast: CAGR (%), 2012-2017, 2017-2023 and 2012-2023
Table 4.5 Market Shares (%) of the Leading Regional OTC Pharmaceutical Markets, 2012, 2017 and 2023
Table 4.6 The US OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.7 Top 10 US OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.8 The Japanese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.9 Top 10 Japanese OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.10 The Chinese OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.11 Top 10 Chinese OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.12 The EU5 OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.13 The EU5 OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by National Market, 2012
Table 4.14 The EU5 OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by National Market, 2018
Table 4.15 The EU5 OTC Pharmaceutical Market: Revenues ($bn) and Market Shares (%) by National Market, 2023
Table 4.16 Selected EU5 OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.17 The German OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.18 The UK OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.19 The French OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.20 The Italian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.21 The Spanish OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.22 The Russian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.23 Top 8 Russian OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.24 The Indian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.25 Top 10 Indian OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 4.26 The Brazilian OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2012-2023
Table 4.27 Top 5 Brazilian OTC Pharma Companies: OTC Revenues ($m), Net Revenues ($m), 2012
Table 5.1 Top 10 OTC Pharmaceutical Manufacturers: Revenues ($bn) and Market Shares (%), 2012
Table 5.2 The World OTC Pharma Market Forecast: Revenues ($bn), AGR (%), CAGR (%) by Leading Company, 2012-2023
Table 5.3 Bayer: Overview, 2012
Table 5.4 Bayer OTC Brands, 2013
Table 5.5 Bayer: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.6 Bayer Aspirin: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.7 Boehringer Ingelheim: Overview, 2012
Table 5.8 Boehringer Ingelheim OTC Brands, 2013
Table 5.9 Boehringer Ingelheim: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.10 GSK: Overview, 2012
Table 5.11 GSK OTC Brands, 2013
Table 5.12 GSK: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.13 Panadol OTC Products, 2013
Table 5.14 Panadol: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.15 Nicorette OTC Products, 2013
Table 5.16 Johnson & Johnson: Overview, 2012
Table 5.17 Johnson & Johnson OTC Brands, 2013
Table 5.18 Johnson & Johnson: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.19 Tylenol OTC Products, 2013
Table 5.20 Johnson & Johnson: Tylenol Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.21 Nicorette OTC Products, 2013
Table 5.22 Merck: Overview, 2012
Table 5.23 Merck OTC Brands, 2013
Table 5.24 Merck: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.25 Claritin OTC: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.26 Novartis: Overview, 2012
Table 5.27 Novartis OTC Brands, 2013
Table 5.28 Novartis: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.29 Perrigo: Overview, 2012
Table 5.30 Perrigo: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.31 Pfizer: Overview, 2012
Table 5.32 Pfizer OTC Brands, 2013
Table 5.33 Pfizer: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.34 Advil OTC Products, 2013
Table 5.35 Advil: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.36 Procter & Gamble: Overview, 2012
Table 5.37 Reckitt Benckiser: Overview, 2012
Table 5.38 Reckitt Benckiser: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.39 Sanofi: Overview, 2012
Table 5.40 Sanofi OTC Brands, 2013
Table 5.41 Sanofi: OTC Sales Forecast ($m), AGR (%), CAGR (%), 2012-2023
Table 5.42 Taisho Pharmaceutical: Overview, 2012
Table 6.1 US OTC Switches By Manufacturer, 2002-2012
Table 6.2 Potential Cough, Cold and Allergy OTC Switches By Active Ingredient, 2013-2023
Table 6.3 Potential Analgesics OTC Switches By Active Ingredient, 2013-2023
Table 6.4 Potential Gastrointestinals OTC Switches By Active Ingredient, 2013-2023
Table 6.5 Potential Dermatologicals OTC Switches By Active Ingredient, 2013-2023
Table 7.1 SWOT Analysis of the OTC Pharmaceutical Market, 2013
Table 7.2 World Population Forecast: Size (bn), AGR (%), CAGR (%), 2013-2023

List of Figures

Figure 2.1 The OTC Pharmaceutical Supply Chain, 2013
Figure 3.1 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category, 2012
Figure 3.2 The World OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.3 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2012-2017
Figure 3.4 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2017-2023
Figure 3.5 The World OTC Pharmaceutical Market: CAGR (%) by Product Category, 2012-2023
Figure 3.6 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category, 2017
Figure 3.7 The World OTC Pharmaceutical Market: Market Shares (%) by Product Category, 2023
Figure 3.8 The Cough, Cold and Allergy OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.9 The Analgesics OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.10 The Gastrointestinals OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.11 The Dermatologicals OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.12 The Smoking Cessation Aids OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 3.13 The Other Products OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.1 The World OTC Pharmaceutical Market: Revenues ($bn) by Region, 2012
Figure 4.2 The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2012
Figure 4.3 The World OTC Pharmaceutical Market Forecast: CAGR (%), 2012-2017
Figure 4.4 The World OTC Pharmaceutical Market Forecast: CAGR (%), 2017-2023
Figure 4.5 The World OTC Pharmaceutical Market Forecast: CAGR (%), 2012-2023
Figure 4.6 The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2017
Figure 4.7 The World OTC Pharmaceutical Market: Market Shares (%) by Region, 2023
Figure 4.8 The US OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.9 The Japanese OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.10 The Chinese OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.11 The EU5 OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.12 The EU5 OTC Pharma Market Forecast: Revenues ($bn), By National Market, 2012-2023
Figure 4.13 The EU5 OTC Pharmaceutical Market: Market Shares (%) by National Market, 2012
Figure 4.14 The EU5 OTC Pharmaceutical Market: Market Shares (%) by National Market, 2018
Figure 4.15 The EU5 OTC Pharmaceutical Market: Market Shares (%) by National Market, 2023
Figure 4.16 The German OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.17 The UK OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.18 The French OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.19 The Italian OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.20 The Spanish OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.21 The Russian OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.22 The Indian OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 4.23 The Brazilian OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 5.1 Leading OTC Pharmaceutical Manufacturers by Market Share (%), 2012
Figure 5.2 Bayer: OTC Sales Forecast ($m), 2012-2023
Figure 5.3 Bayer Aspirin: OTC Sales Forecast ($m), 2012-2023
Figure 5.4 Boehringer Ingelheim: OTC Sales Forecast ($m), 2012-2023
Figure 5.5 GSK: OTC Sales Forecast ($m), 2012-2023
Figure 5.6 Panadol: OTC Sales Forecast ($m), 2012-2023
Figure 5.7 Johnson & Johnson: OTC Sales Forecast ($m), 2012-2023
Figure 5.8 Johnson & Johnson: Tylenol Sales Forecast ($m), 2012-2023
Figure 5.9 Merck: OTC Sales Forecast ($m), 2012-2023
Figure 5.10 Claritin OTC: OTC Sales Forecast ($m), 2012-2023
Figure 5.11 Novartis: OTC Sales Forecast ($m), 2012-2023
Figure 5.12 Perrigo: OTC Sales Forecast ($m), 2012-2023
Figure 5.13 Pfizer: OTC Sales Forecast ($m), 2012-2023
Figure 5.14 Advil: OTC Sales Forecast ($m), 2012-2023
Figure 5.15 Reckitt Benckiser: OTC Sales Forecast ($m), 2012-2023
Figure 5.16 Sanofi: OTC Sales Forecast ($m), 2012-2023
Figure 6.1 Number Of FDA-Approved OTC Switches, By Year, 1976-2013
Figure 6.2 Number Of FDA-Approved OTC Switches, By 5-Year Periods, 1976-2013
Figure 7.1 World Population Forecast: Size (bn), 2013-2023
Figure 7.2 World 65+ Population Forecast: Size (m), 2013-2023
Figure 7.3 Porter's Five Forces Analysis of the OTC Pharmaceutical Market, 2013
Figure 9.1 The World OTC Pharmaceutical Market: Revenues ($bn) by Product Category, 2012
Figure 9.2 The World OTC Pharmaceutical Market: Revenues ($bn) by Region, 2012
Figure 9.3 The World OTC Pharma Market Forecast: Revenues ($bn), 2012-2023
Figure 9.4 World Population Forecast: Size (bn), 2013-2023
Figure 9.5 World 65+ Population Forecast: Size (m), 2013-2023

Companies Listed

Aché Laboratórios Farmacêuticos
Actavis
Adams Respiratory Therapeutics
AFIPA (France)
Agis Industries (subsidiary of Perrigo)
Akrikhin
Alacer (acquired by Pfizer)
Alcon (subsidiary of Novartis)
Allergan
Alliance Boots
American Medical Association
American Pharmacists Association
American Society of Association Executives
American Society of Health-System Pharmacists
Amerisource Bergen
Arena Pharmaceuticals
Ascherm B.F. & Company
Aspen Pharmacare
Association of the European Self-Medication Industry (AESGP)
Astellas Pharma
AstraZeneca
Aurobindo
Aventis (now part of Sanofi)
Bayer
Ben Venue Laboratories (subsidiary of Boehringer Ingelheim)
Biofermin Pharmaceutical (subsidiary of Taisho)
BMP Sunstone (acquired by Sanofi)
Boehringer Ingelheim
Brazilian Health Surveillance Agency (ANVISA)
Bristol-Myers Squibb
Brookings Institution
Candem Pharma (acquired by Sanofi)
Cardinal Health
Celesio
Chattem (subsidiary of Sanofi)
Chiese Farmaceutici
China Resources Sanjiu Pharmaceutical
Chiron Corporation (subsidiary of Novartis)
CIBA VISION (subsidiary of Novartis)
Cilag GmbH (subsidiary of Johnson & Johnson)
Cipla
CISCA (Compania Internacional de Comercio, S.A.P.I. de C.V.) (acquired by Taisho)
Consumer Health Products Association (CHPA)
Costco
CSPC (China Shijiazhuang Pharmaceutical Group)
CVS
Daiichi Sankyo
Dalkhimpharm
Department of Health and Human Services (US)
Dexcel Pharma
District of Columbia Bar
Dollar General
Dr. Reddy's Laboratories
Drug Information Association
Duramed Pharmaceuticals (acquired by Teva)
Eisai
Elan (acquired by Perrigo)
Eli Lilly and Company
EMS
Engelberg Center for Health Care Reform
Eurofarma
European Medicines Agency (EMA)
Facebook
Federal Trade Commission
Ferrosan (consumer healthcare division acquired by Pfizer)
Fosun Pharma
Fougera Pharmaceuticals (subsidiary of Novartis)
French Ministry of Health
Galderma
Galpharm Healthcare (subsidiary of Perrigo)
German Ministry of Health
Gillette (subsidiary of Procter & Gamble)
Golong Medicine (acquired by Reckitt Benckiser)
GSK
Guangzhou Pharmaceutical
Harbin Pharmaceutical Group
Hisamitsu
Hoepharma Holdings (subsidiary of Taisho)
Human Genome Sciences (subsidiary of GSK)
Hypermarcas
INSIGHT Pharmaceuticals (formerly Heritage Brands)
Ipca Laboratories
Janssen Pharmaceutica (subsidiary of Johnson & Johnson)
JB Chemicals and Pharmaceuticals
Jenapharm (subsidiary of Bayer)
Johnson & Johnson
Kangmei Pharmaceutical
Kernpharm (acquired by Sanofi)
Kowa Group
Laboratoire Oenobiol (acquired by Sanofi)
Laboratorios Diba
Leonard Davis Institute for Health Economics
Lion Corporation
L'Oréal
Lupin Limited
Mankind Pharma
Marico
Materia Medica
McKesson Corporation
McNeil Consumer Healthcare (subsidiary of Johnson & Johnson)
Medicines and Healthcare Products Regulatory Agency (MHRA) (UK)
Menarini Group
Merck & Co. (Merck)
Merck Consumer Pharmaceuticals Co. (subsidiary of Johnson & Johnson)
Ministry of Health (China)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Ministry of Human Resources and Social Security (MOHRSS) (China)
Minsheng Pharmaceuticals (acquired by Sanofi)
Mitsubishi Tanabe Pharma
Mylan
National Development and Reform Commission (China)
National Health Service (NHS) (UK)
National Pharmaceutical Pricing Authority (NPPA) (India)
Nepentes (acquired by Sanofi)
Nepstar
Nichi-Iko Pharmaceutical Co.
North China Pharmaceutical
Novartis
Nycomed (acquired by Takeda)
Obolensk
Omega Pharma
Orion Laboratories (subsidiary of Perrigo)
Otsuka Pharmaceutical
Paras Pharmaceuticals (acquired by Reckitt Benckiser)
Pernix
Perrigo
Pfizer
Pharmstandard
Philadelphia College of Pharmacy
Phoenix
Pierre Fabre
Prestige Brands
Procter & Gamble
Purdue Pharma
Ranbaxy Laboratories (subsidiary of Daiichi Sankyo)
Ratiopharm (acquired by Teva)
Reckitt Benckiser
Recordati
Roche
Roche Consumer Health (acquired by Bayer)
Rohto Pharmaceutical
Roxane Laboratories (subsidiary of Boehringer Ingelheim)
Sam's Club
Sandoz (subsidiary of Novartis)
Sanofi
Sanofi Pasteur (subsidiary of Sanofi)
Sato Pharmaceutical
Schering AG (acquired by Bayer)
Schering-Plough (subsidiary of Merck)
Schiff Nutrition (acquired by Reckitt Benckiser)
Sepracor
Sergeant's (acquired by Perrigo)
Shanghai Pharmaceuticals
Shionogi
Sinopharm
Somaxon Pharmaceuticals (subsidiary of Pernix)
Sotex
SSL International (subsidiary of Reckitt Benckiser)
SSP Co. (acquired by Boehringer Ingelheim)
STADA Arzneimittel
State Administration of Industry and Commerce (SAIC) (China)
State Administration of Quality Supervision Inspection and Quarantine (AQSIQ) (China)
State Food and Drug Administration (SFDA) (China)
Steigerwald (acquired by Bayer)
Stiefel Laboratories (subsidiary of GSK)
Sun Pharma
Synthélabo (now part of Sanofi)
Synthes Inc (acquired by Johnson & Johnson)
Taisho Pharmaceutical
Taisho Toyama Pharmaceutical (Taisho/Toyama Chemical Co. Joint venture)
Takeda Pharmaceutical
Target
Teuto
Teva
Torrent Pharmaceuticals
Tufts Center for the Study of Drug Development
Twitter
U.S. Food and Drug Administration (FDA) (US)
Unico Holdings
United Nations Department for Economic and Social Affairs
Universal Medicare (acquired by Sanofi)
University of Amsterdam
University of Pennsylvania
University of the Sciences in Philadelphia
Valenta
Velcera (acquired by Perrigo)
Veropharm
Veteran Affairs Medical Center, Philadelphia
ViiV Healthcare (GSK/Pfizer joint venture)
Vivus Inc.
Walgreens
Walmart
Warner Chilcott
Wockhardt
World Bank
World Self-Medication Industry (WSMI)
World Trade Organization (WTO)
Wyeth (subsidiary of Pfizer)
Yangtze River Pharmaceutical
Zydus Cadila

To order this report: World OTC Pharmaceutical Market 2013-2023
http://www.reportlinker.com/p0943305/World-OTC-Pharmaceutical-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Over-The-Counter_Drug


Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.